bluuebunny/crossref_metadata_2025_split huggingface dataset:
Expression of mir-34c-5p and mir-150-5p in nasopharyngeal carcinoma and up-regulated expression after invasion and apoptosis of nasopharyngeal carcinoma cells*
Authors: Zhou Xiaojun , Lin Baorui , Wang Yun 
Published: June 2023

Abstract

Objective
MiRNAs are closely related to tumors, and we hypothesized there is specific miR expression in nasopharyngeal carcinoma (NPC). We intended to investigate the expression of mir-34c-5p and mir-150-5p in NPC and to investigate the effects of mir-34c-5p and mir-150-5p on apoptosis and invasion following up-regulated expression in HNE1 NPC cells.

Methods
MiR-34c-5p and miR-150-5p expression levels in 30 individual cases of NPC and nasopharyngitis were detected with gene chip and qRT-PCR techniques. miR-34c-5p and miR-150-5p were transfected into the NPC cell line HNE1 via liposomes. Their expression levels were detected with qRT-PCR, apoptosis was evaluated by flow cytometry, and invasion ability was assessed via Transwell migration assay.

Results
MiR-150-5p expression levels in NPC and nasopharyngitis were 0.165 ± 0.092 and 1.062 ± 0.280 respectively, and miR-34c-5p expression levels in NPC and nasopharyngitis were 0.417 ± 0.220 and 1.385 ± 0.739, respectively, which indicated miR-34c-5p and miR-150-5p were weakly expressed in NPC. Apoptosis rates in HNE1 cells transfected by miR-34c-5p and miR-150-5p were increased, by 12.7% and 7.6%, respectively, which were significantly higher compared to blank control (3.9%). The Transwell assay demonstrated that invasive HNE1 cell counts were 32.00 ± 2.00 and 28.33 ± 2.08, respectively, compared to 60.66 ± 8.50 in the blank control (P < 0.001).

Conclusion
MiR-34c-5p and miR-150-5p are lowly expressed in NPC, and their down-regulation may be associated with NPC.
Megakaryocyte aplastic thrombocytopenia after CAR T-cell therapy in a patient with multiple myeloma: A case report
Authors: Liu Shangqin , Gui Chengsi 
Published: June 2023

Abstract
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment strategy for hematologic malignancies. The success of CAR T-cell therapy in treating leukemia and lymphoma has promoted its development for multiple myeloma (MM), and the initial results of CAR T cell therapy have been encouraging. CAR T-cell therapy target antigens that have been clinically evaluated in MM; these antigens include CD19, B cell maturation antigen (BCMA), CD38, and CD138. A barrier to the widespread use of CAR T-cell therapy is its toxicity, primarily cytokine release syndrome (CRS), and neurologic toxicity. This study reports a patient with refractory MM who also developed megakaryocyte aplastic thrombocytopenia after receiving CAR T-cell therapy; such a case or the unusual side effects involving medications are yet unreported. There are risks in using cyclosporine and other immunosuppressants that may lead to MM recurrence as the use of such substances is contradictory to previous treatments; therefore, we temporarily administered platelet infusion as supportive care. Thus far, the condition of the patient has been steady and the patient regularly takes blood test in the hospital.
Efficacy and safety of berberine in the prophylactic treatment of acute radiation proctitis in postoperative patients with cervical cancer: a randomized controlled study*
Authors: Qin Kai , Cheng Yi , Yuan Xianglin , Zhang Jing , Huang Le 
Published: June 2023

Abstract

Objective
The aiom of this study was to study the efficacy and safety of berberine as a prophylactic treatment of acute radiation proctitis in postoperative patients with cervical cancer.

Methods
A total of 120 postoperative patients with cervical cancer were enrolled between July 2016 and October 2019, and randomly divided into a treatment group (berberine 300 mg three times a day, n = 60) and a control group (receiving vitamin C tablets, 100 mg three times a day; n = 60) using the random number table method. All patients received pelvic intensity-modulated radiation therapy (IMRT) and concurrent sensitizing chemotherapy weekly. The difference in the percentage of irradiation volume to the rectum and small intestine as well as the incidence, onset time, severity, and duration of acute radiation proctitis and cystitis during radiotherapy were compared between the two groups. The completion rate, completion time, number of chemotherapy sessions, and quality of life during radiotherapy were also compared.

Results
There were no statistical differences in age, FIGO stage, pathological type, complications, high-risk factors, and rectum and small intestine irradiation dose distribution (V20, V30, V40, and V50) between the two groups (P > 0.05). No acute radiation proctitis of grade 3 or above occurred in the two groups. There was no significant difference in the incidence of acute radiation cystitis, grade 2 acute radiation proctitis, completion rate of IMRT, and frequency of sensitization chemotherapy between the two groups. After prophylactic treatment with berberine, the incidence of grade 1 acute radiation proctitis, occurrence of grade 1 radiation proctitis, and completion time of radiotherapy in the treatment group were significantly lower than those in the control group (P < 0.05). The SF-36 score of the treatment group after radiotherapy was 67.53 ± 4.21, which was significantly better than that of the control group (64.90 ± 6.32; P < 0.05). The incidence of grade 3-4 neutropenia in the treatment group was 10% and lower than that in the control group (31.7%, P = 0.003). No adverse reactions related to berberine were observed.

Conclusion
Prophylactic prescription with oral berberine can reduce the incidence, onset time, and duration of grade 1 acute radiation proctitis, and improve the quality of life of postoperative patients with cervical cancer receiving concurrent chemoradiotherapy.
A case report of iodine-125 seed placement during operation for the treatment of advanced gallbladder carcinoma with septic shock*
Authors: Zhong Zhuo , Gao Fei , Lv Zhuo , Zhong Zhihui , Long De 
Published: June 2023

Abstract
This case report describes a patient with advanced gallbladder cancer who developed septic shock associated with iodine-125 (125I) seed implantation. The treatment process is described to provide a clinical reference for similar cases. A 52-year-old woman with recurrence of advanced gallbladder cancer underwent 125I seed implantation and developed postoperative sepsis with septic shock. The blood culture suggested infection with Aeromonas caviae and Enterococcus faecalis. Vancomycin and imipenem were immediately administered according to the drug sensitivity results, along with immunoglobulin therapy and vasoactive drugs. The patient’s condition gradually stabilized after comprehensive treatment. Sepsis with septic shock is a rare but potentially fatal complication of 125I seed implantation. Timely administration of broad-spectrum antibiotics, immunoglobulin therapy, and vasoactive drugs is very important to stabilize the patient’s condition. Our treatment of this patient can serve as a reference for clinicians to manage this complication in similar cases.
Construction and validation of an immune-related lncRNA prognostic model for rectal adenocarcinomas*
Authors: Jian Danni , Cheng Yi , Zhang Jing , Qin Kai 
Published: June 2023

Abstract

Objective
This study aimed to construct a prognostic model for rectal adenocarcinomas based on immune-related long noncoding RNAs (lncRNAs) and verify its prediction efficiency.

Methods
Transcript data and clinical data of rectal adenocarcinomas were downloaded from The Cancer Genome Atlas (TCGA) database. Perl software (strawberry version) and R language (version 3.6.1) were used to analyze the immune-related genes and immune-related lncRNAs of rectal adenocarcinomas, and the differentially expressed immune-related lncRNAs were screened according to the criteria |log2FC| > 1 and P < 0.05. The key immune-related lncRNAs were screened using single-factor Cox regression analysis and lasso regression analysis. Multivariate Cox regression analysis was performed to construct an immune-related lncRNA prognostic model using the risk scores. Next, we evaluated the effectiveness of the model through Kaplan-Meier (K-M) survival analysis, ROC curve analysis, and independent prognostic analysis of clinical features. In addition, prognostic biomarkers of immune-related lncRNAs in the model were analyzed by K-M survival analysis.

Results
In this study, we obtained gene expression profile matrices of 89 rectal adenocarcinomas and 2 paracancerous specimens from TCGA database and applied immunologic signatures to these transcripts. Through R and Perl software analysis, we obtained 847 immune-related lncRNAs and 331 protein-encoded immune-related genes in rectal adenocarcinomas. Eight important immune-related lncRNAs related to the prognosis of rectal adenocarcinomas were identified using univariate Cox regression and lasso regression analysis. Furthermore, four immune-related lncRNAs were identified as prognostic markers of rectal adenocarcinomas via multivariate Cox regression analysis. The prognostic risk model was as follows: risk score = (-4.084) * expression LINC01871 + (3.112) * expression AL158152.2 + (7.616) * expression PXN-AS1 + (-0.867) * expression HCP5. The independent prognostic effect of the rectal adenocarcinoma risk score model was revealed through K-M analysis, ROC curve analysis, and univariate, and multivariate Cox regression analysis (P = 0.035). LINC01871 (P = 0.006), PXN-AS1 (P = 0.008), and AL158152.2 (P = 0.0386) were closely correlated with the prognosis of rectal adenocarcinomas through the K-M survival analysis.

Conclusion
We constructed a prognostic model of rectal adenocarcinomas based on four immune-related lncRNAs by analyzing the data based on TCGA database, with high prediction accuracy. We also identified two biomarkers with poor prognosis (PXN-AS1 and AL158152.2) and one biomarker with good prognosis (LINC01871).
The clinical efficacy of percutaneous ethanol-lipiodol injection (PEI) combined with high-intensity focused ultrasound (HIFU) for small hepatocellularcarcinoma in special or high-risk locations*
Authors: Zou Xiaoli , Zhao Changzhi , Wang Tao , Jia Li , Feng Zhongyi , Wang Xiaoguang , Wei Lei , Liu Xiaobei 
Published: June 2023

Abstract

Objective
The objective of this study was to explore the short-term effects and postoperative complications of ultrasound-guided percutaneous ethanol-lipiodol injection (PEI) combined with high-intensity focused ultrasound (HIFU) for the treatment of small hepatocellular carcinoma in a special or high-risk location.

Methods
Forty patients with small liver cancer in a special or high-risk location were randomly divided into two groups: 20 patients were treated with PEI combined with HIFU (P + H group), and 20 patients were treated with HIFU alone (H group). There were no significant differences in average age, liver function, tumor location, tumor number, or tumor size between the two groups (P > 0.05).

Results
Significant differences were observed in ablation parameters between the two groups (P < 0.05). Under the same power, ablation rates of the P + H group were significantly higher than those in the H group, and postoperative complications in the P + H group were significantly lower than those in the H group (P < 0.05).

Conclusion
The combination of PEI and HIFU has better clinical value than HIFU alone for small-cell liver cancer in special or high-risk locations.
KIF15 expression characteristics: Relevance toneo-adjuvant chemotherapy efficacy in breast cancer*
Authors: Dong Mengting , Li Chunyang , Jiapaer Patiguli , Li Xiaofei , Xue Xiaohong , Jiang Ke , Sheng Jiayu 
Published: June 2023

Abstract

Objective
The relationship between the expression of kinesin family member 15 (KIF15) and clinicopathological features in breast cancer (BC) remains controversial. In this study, we aimed to explore the influence of KIF15 expression on the efficacy of neoadjuvant chemotherapy (NAC) and evaluate its clinical value in predicting prognosis for BC patients.

Methods
Immunohistochemistry was used to detect KIF15 expression in 93 BC patients undergoing NAC to analyze the relationship between KIF15 expression and clinical efficacy and analytical parameters.

Results
Of the 93 BC patients enrolled, 24.73% who underwent NAC had higher KIF15 expression levels, showing positive correlations with ER, HER-2, Ki67, and lymph node metastasis (P < 0.05). The clinical benefit of NAC was 70.97%, and the major histological response (MHR) rate was 61.29%. The effective therapeutic rate in patients with high KIF15 expression was 95.65%, while the MHR rate was 65.22%. Various molecular BC subtypes with varied clinical and pathological responses exhibited correlation to a large extent. Of all the BC patients studied, 84% of the triple-negative breast cancer (TNBC) patients were evaluated as clinically effective, and 52% of the TNBC patients were evaluated as pathologically effective, and these values were significantly higher than those of the other molecular types (P < 0.05). The expression of KIF15 in 25 TNBC patients showed positive correlations with lymph node metastasis.

Conclusion
Overexpression of KIF15 was shown to increase BC sensitivity to chemotherapy and demonstrated better outcomes.
Mechanism of tumor synthetic lethal-related targets
Authors: Zhang Yuhang , Xu Peng 
Published: June 2023

Abstract
Synthetic lethality is becoming more and more important in the precise treatment of oncology. Malignant tumors caused by gene mutations involve a complex DNA signaling process, and inhibition of DNA signaling in different ways may more effectively control the occurrence and development of tumors. Inhibition of tumor paired lethal genes effectively kills tumor cells, and more and more novel drugs that inhibit tumors are developing in this direction. This article reviews the synthetic lethal theory and discusses selection of drugs to target mutated genes in common solid tumors. The synthetic lethal gene pairs, representative targeted drugs, and related characteristics of four tumor types: lung cancer, breast cancer, colon cancer and prostate cancer, are systematically reviewed.
Identification of microRNA-21 as a valuable diagnostic marker of oral squamous cell carcinoma and potential target*
Authors: Yang Hua , Wei Yuxue , Liu Gangli 
Published: June 2023

Abstract

Objective
The aim of the study was to summarize the diagnostic value of miR-21 as a biomarker in oral squamous cell carcinoma (OSCC) using a review of the literature and data from the cancer genome atlas (TCGA) database.

Methods
Data from TCGA database was sorted and analyzed by bioinformatics to determine the expression level of miR-21 in OSCC. Further, we searched for relevant articles in Embase, PubMed/Medline, Scopus, and Web of Science published before March 2021, extracted the data, and conducted quality assessment. The bivariate meta-analysis model with Stata 16.0 was used to analyze the diagnostic value of miR-21 for OSCC.

Results
A total of 304 related articles were identified, and seven were selected for meta-analysis. The diagnostic results after analysis were as follows: sensitivity 0.76 [95% confidence interval (CI), 0.57-0.88]; specificity 0.77 (95% CI, 0.58-0.89); positive likelihood ratio 3.34 (95% CI, 1.58-7.08); negative likelihood ratio 0.31 (95% CI, 0.15-0.63); diagnostic odds ratio 10.75 (95% CI, 2.85-40.51); and area under the curve 0.83 (95% CI, 0.80-0.86). The Deeks’ funnel chart showed that there was no potential bias (P = 0.54). Prediction analysis of the potential target genes of miR-21 was performed via the biological website, and DAVID was used to cross target genes for gene ontology (GO) annotation function analysis.

Conclusion
The results showed that miR-21-3p and miR-21-5p were significantly more highly expressed in OSCC tissues than in normal tissues (P < 0.05), and the results of the meta-analysis indicated that they could be used as potential biomarkers in the diagnosis of OSCC. In addition, 58 potential target genes of miR-21 were significantly enriched in 28 GO annotation functional pathways, which provided a biological basis for further clinical diagnostic value research.
Cone beam computed tomography-guided differences among registration methods for lung cancer and the effects of tumor position, treatment model, and tumor size on positioning errors*
Authors: Du Jiayu , Tang Jie , Zhang Qian , Ma Xiaojie 
Published: June 2023

Abstract

Objective
To explore the differences in three different registration methods of cone beam computed tomography (CBCT)-guided down-regulated intense radiation therapy for lung cancer as well as the effects of tumor location, treatment mode, and tumor size on registration.

Methods
This retrospective analysis included 80 lung cancer patients undergoing radiotherapy in our hospital from November 2017 to October 2019 and compared automatic bone registration, automatic grayscale (t + r) registration, and automatic grayscale (t) positioning error on the X-, Y-, and Z-axes under three types of registration methods. The patients were also grouped according to tumor position, treatment mode, and tumor size to compare positioning errors.

Results
On the X-, Y-, and Z-axes, automatic grayscale (t + r) and automatic grayscale (t) registration showed a better trend. Analysis of the different treatment modes showed differences in the three registration methods; however, these were not statistically significant. Analysis according to tumor sizes showed significant differences between the three registration methods (P < 0.05). Analysis according to tumor positions showed differences in the X- and Y-axes that were not significant (P > 0.05), while the autopsy registration in the Z-axis showed the largest difference in the mediastinal and hilar lymph nodes (P < 0.05).

Conclusion
The treatment mode was not the main factor affecting registration error in lung cancer. Three registration methods are available for tumors in the upper and lower lungs measuring < 3 cm; among these, automatic gray registration is recommended, while any gray registration method is recommended for tumors located in the mediastinal hilar site measuring < 3 cm and in the upper and lower lungs ≥ 3 cm.
GFPT2 pan-cancer analysis and its prognostic and tumor microenvironment associations*
Authors: Zhang Jiachen , Wang Ting , Wei Siang , Chen Shujia , Bi Juan 
Published: June 2023

Abstract

Objective
Glutamine fructose-6-phosphate transaminase 2 (GFPT2) is involved in a wide range of biological functions in human cancer. However, few studies have comprehensively analyzed the correlation between GFPT2 and different cancer prognoses and tumor microenvironments (TMEs).

Methods
We evaluated the expression level and prognostic value of GFPT2 using updated public databases and multiple comprehensive bioinformatics analysis methods and explored the relationship between GFPT2 expression and immune infiltration, immune neoantigens, tumor mutational burden (TMB), and microsatellite instability in pan-cancer.

Results

GFPT2 was highly expressed in five cancers. GFPT2 expression correlates with the prognosis of several cancers from The Cancer Genome Atlas (TCGA) and is significantly associated with stromal and immune scores in pan-cancer. High GFPT2 expression in BLCA, BRCA, and CHOL was positively correlated with the infiltration of immune cells, such as B-cells, CD4+ T, CD8+ T cells, dendritic cells, neutrophils, and macrophages.

Conclusion
High GFPT2 expression may modify the outcomes of patients with BLCA, BRCA, or CHOL cancers by increasing immune cell infiltration. These findings may provide insights for further investigation into GFPT2 as a potential target in pan-cancer.
Special IgD-λ type multiple myeloma based on bone marrow cell morphology: A case report
Authors: Zhang Xiaofang , Zhang Yanqing , Zhang Yungang , Wan Chuanke , Xu Ling , Li Ruimin 
Published: June 2023

Abstract
We aimed to explore the changes of laboratory indexes of IgD- λ type multiple myeloma with special cell morphology, and to improve the cognition of IgD-λ type MM. To explore the changes of laboratory indexes of IgD-λ type 1 multiple myeloma with special cell morphology, and to improve the cognition of IgD-λ type MM. The morphology of bone marrow cells, immunofixation electrophoresis, serum free light chain (sFLC) and other detection indexes of a patient with IgD-λ type MM treated in Handan Central Hospital in December 2020 were analyzed. The patient bone marrow smears showed 62% of abnormal cells-which were distributed in clusters and resembled lymphoma and metastatic cancer cells. The Flowcytometry indicates that the cell is a plasma cell tumor.Immunoglobulin IgG, IgA and IgM were all lower than the normal range.There is a monoclonal light chain λ component in immunofixation electrophoresis.The serum free light chain λ was 2700.00 mg/ L, light chain k/λ is 0.0023, the high of serum calcium, LDH, β2 microglobulin. IgD-λ type MM is a rare type of MM. The age of onset is young, the invasiveness is strong, the prognosis is poor, the clinical manifestation is complex, and it is easy to be misdiagnosed or missed. The analysis of the clinical symptoms and laboratory characteristics of the disease plays a positive role in the diagnosis, treatment and prognosis of the disease.
Gene mutation analysis and immune checkpoint therapy in head and neck squamous cell carcinoma*
Authors: Yang Hua , Wei Yuxue , Liu Gangli 
Published: June 2023

Abstract
Immune checkpoint inhibitors (ICI), represented by blocked programmed cell death-1 (PD-1), is a group of novel medicines for anti-tumor immunotherapy. It has been approved by the U.S. Food and Drug Administration (FDA) in recent years for relapsed or metastatic head and neck squamous cell carcinoma (HNSCC), and brings promising treatment prospects. However, the instability caused by tumor gene mutations significantly compromises the therapeutic effect of ICI. Therefore, the identification and analysis of HNSCC gene mutations can further guide and optimize the application of ICIs in HNSCC. In this study, we preliminarily described the clinical research progress of ICI therapy and the potential immune escape mechanism in HNSCC. An overview of complete HNSCC gene mutation results was generated from the bioinformatics study of TCGA database to further explain and analyze the relevant molecular mechanisms, which may aid in designing future personalized therapeutic strategies for HNSCC patients.